Several recent large placebo-controlled trials of SGLT2 inhibitors evaluated the effects on cardiovascular and renal outcomes in type 2 diabetes mellitus (T2DM) patients. The gene discussed is SLC5A2; the disease is type 2 diabetes mellitus.